Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Stomach Ulcer D013276 75 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Breast Neoplasms D001943 24 associated lipids
Neoplasms D009369 13 associated lipids
Pain D010146 64 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Fatty Liver D005234 48 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hypotension D007022 41 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Melanoma D008545 69 associated lipids
Weight Gain D015430 101 associated lipids
Hyperemia D006940 25 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Obesity D009765 29 associated lipids
Bradycardia D001919 13 associated lipids
Urinary Bladder Diseases D001745 4 associated lipids
Alzheimer Disease D000544 76 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Neuroblastoma D009447 66 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Nervous System Diseases D009422 37 associated lipids
Ataxia D001259 20 associated lipids
Brain Edema D001929 20 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Brain Ischemia D002545 89 associated lipids
Epilepsy D004827 35 associated lipids
Seizures D012640 87 associated lipids
Nerve Degeneration D009410 53 associated lipids
Peptic Ulcer D010437 19 associated lipids
Hypertension D006973 115 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Substance-Related Disorders D019966 2 associated lipids
Hepatitis D006505 11 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Brain Damage, Chronic D001925 6 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Fever D005334 35 associated lipids
Bronchial Spasm D001986 18 associated lipids
Morphine Dependence D009021 9 associated lipids
Shock, Septic D012772 11 associated lipids
Cough D003371 19 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Catalepsy D002375 30 associated lipids
Migraine Disorders D008881 11 associated lipids
Cardiomyopathy, Dilated D002311 15 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Learning Disorders D007859 11 associated lipids
Hyperkinesis D006948 11 associated lipids
Hyperinsulinism D006946 27 associated lipids
Muscle Spasticity D009128 5 associated lipids
Hypothermia D007035 19 associated lipids
Celiac Disease D002446 16 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Hypertension, Portal D006975 12 associated lipids
Insulin Resistance D007333 99 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Brain Concussion D001924 5 associated lipids
Endotoxemia D019446 27 associated lipids
Anorexia D000855 8 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Memory Disorders D008569 33 associated lipids
Parkinson Disease, Secondary D010302 17 associated lipids
Overweight D050177 11 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Neuralgia D009437 28 associated lipids
Fibromyalgia D005356 4 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Bulimia D002032 3 associated lipids
Sleep Deprivation D012892 5 associated lipids
Urinary Incontinence D014549 4 associated lipids
Vascular System Injuries D057772 2 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Pregnancy, Ectopic D011271 5 associated lipids
Ocular Hypotension D015814 2 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Impotence, Vasculogenic D018783 4 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Picornaviridae Infections D010850 4 associated lipids
Somatosensory Disorders D020886 1 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Maccarrone M et al. Anandamide activates human platelets through a pathway independent of the arachidonate cascade. 1999 FEBS Lett. pmid:10214961
Schmid PC et al. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. 1995 FEBS Lett. pmid:7498458
Braud S et al. Activation of rabbit blood platelets by anandamide through its cleavage into arachidonic acid. 2000 FEBS Lett. pmid:10760504
van der Stelt M et al. Dioxygenation of N-linoleoyl amides by soybean lipoxygenase-1. 1997 FEBS Lett. pmid:9271222
Maccarrone M and Finazzi-Agró A Platelet activation: a new vascular activity of anandamide. 2000 FEBS Lett. pmid:11184253
Fowler CJ Transport of endocannabinoids across the plasma membrane and within the cell. 2013 FEBS J. pmid:23441874
Stark K et al. Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide. 2008 FEBS J. pmid:18549450
van der Stelt M et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. 2005 FASEB J. pmid:15894565
Mascolo N et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice. 2002 FASEB J. pmid:12397089
Varga K et al. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. 1998 FASEB J. pmid:9707176
Bátkai S et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. 2007 FASEB J. pmid:17327359
Karwad MA et al. The role of CB in intestinal permeability and inflammation. 2017 FASEB J. pmid:28404744
Baker D et al. Endocannabinoids control spasticity in a multiple sclerosis model. 2001 FASEB J. pmid:11156943
D'Argenio G et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. 2006 FASEB J. pmid:16403786
Bifulco M et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. 2001 FASEB J. pmid:11687506
Di Marzo V et al. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. 2000 FASEB J. pmid:10877836
Berdyshev EV et al. Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. 2001 FASEB J. pmid:11641243
Jones S and Howl J Cannabinoid receptor systems: therapeutic targets for tumour intervention. 2003 Expert Opin. Ther. Targets pmid:14640910
Lory P and Chemin J Towards the discovery of novel T-type calcium channel blockers. 2007 Expert Opin. Ther. Targets pmid:17465728
Bambico FR and Gobbi G The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. 2008 Expert Opin. Ther. Targets pmid:18851692
Wise ML et al. Synthesis and cannabinoid receptor binding activity of conjugated triene anandamide, a novel eicosanoid. 1996 Experientia pmid:8575565
Feizi A et al. The preventive effect of cannabinoids on reperfusion-induced ischemia of mouse kidney. 2008 Exp. Toxicol. Pathol. pmid:18571910
Venderova K et al. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. 2005 Exp. Neurol. pmid:15899265
Hansen HS Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. 2010 Exp. Neurol. pmid:20353771
Greco R et al. The endocannabinoid system and migraine. 2010 Exp. Neurol. pmid:20353780
Bhaskaran MD and Smith BN Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy. 2010 Exp. Neurol. pmid:20144892
Kreutz S et al. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. 2007 Exp. Neurol. pmid:17010339
Bir LS and Ercan S Effects of intrathecal anandamide on somatosensory evoked responses in rats. 2006 Exp. Neurol. pmid:16289169
Solbrig MV et al. A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. 2005 Exp. Neurol. pmid:16022863
Morgese MG et al. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. 2007 Exp. Neurol. pmid:17900568
Köse S et al. Human bone marrow mesenchymal stem cells secrete endocannabinoids that stimulate in vitro hematopoietic stem cell migration effectively comparable to beta-adrenergic stimulation. 2018 Exp. Hematol. pmid:29030083
Matsuda S et al. Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. 1997 Exp. Eye Res. pmid:9245900
Jumpertz R et al. Circulating endocannabinoids and N-acyl-ethanolamides in patients with sleep apnea--specific role of oleoylethanolamide. 2010 Exp. Clin. Endocrinol. Diabetes pmid:20429051
De Petrocellis L et al. Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. 2007 Exp. Cell Res. pmid:17428469
Frampton G et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. 2010 Exp. Cell Res. pmid:20347808
Grimaldi C et al. Anandamide inhibits adhesion and migration of breast cancer cells. 2006 Exp. Cell Res. pmid:16343481
Prestifilippo JP et al. Inhibition of salivary secretion by activation of cannabinoid receptors. 2006 Exp. Biol. Med. (Maywood) pmid:16946411
Wiley JL et al. A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. 2004 Exp Clin Psychopharmacol pmid:15301634
Burkey RT and Nation JR (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure. 1997 Exp Clin Psychopharmacol pmid:9260067
Gratzke C et al. Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. 2010 Eur. Urol. pmid:19147270
Prieto D Editorial comment on: localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. 2010 Eur. Urol. pmid:19147273
Holt S et al. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. 2007 Eur. J. Pharmacol. pmid:17397826
Rodella LF et al. AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation. 2005 Eur. J. Pharmacol. pmid:15680264
Wheal AJ and Randall MD Effects of hypertension on vasorelaxation to endocannabinoids in vitro. 2009 Eur. J. Pharmacol. pmid:19100733
Beltramo M and Piomelli D Anandamide transport inhibition by the vanilloid agonist olvanil. 1999 Eur. J. Pharmacol. pmid:9920187
Stengel PW et al. Pulmonary actions of anandamide, an endogenous cannabinoid receptor agonist, in guinea pigs. 1998 Eur. J. Pharmacol. pmid:9754939
Vann RE et al. Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. 2009 Eur. J. Pharmacol. pmid:19470387
Ralevic V et al. Cannabinoid activation of recombinant and endogenous vanilloid receptors. 2001 Eur. J. Pharmacol. pmid:11672565
Wallace MJ et al. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. 2002 Eur. J. Pharmacol. pmid:12359270
Kelley BG and Thayer SA Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors. 2004 Eur. J. Pharmacol. pmid:15288572
O'Sullivan SE et al. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. 2005 Eur. J. Pharmacol. pmid:15659311
Orliac ML et al. Increases in vanilloid TRPV1 receptor protein and CGRP content during endotoxemia in rats. 2007 Eur. J. Pharmacol. pmid:17482593
Wheal AJ et al. Hydrogen peroxide as a mediator of vasorelaxation evoked by N-oleoylethanolamine and anandamide in rat small mesenteric arteries. 2012 Eur. J. Pharmacol. pmid:22154756
Bouaboula M et al. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. 2005 Eur. J. Pharmacol. pmid:15987634
McQueen DS et al. Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats. 2004 Eur. J. Pharmacol. pmid:15140635
Fowler CJ et al. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. 2004 Eur. J. Pharmacol. pmid:15145699
Romano MR and Lograno MD Involvement of the peroxisome proliferator-activated receptor (PPAR) alpha in vascular response of endocannabinoids in the bovine ophthalmic artery. 2012 Eur. J. Pharmacol. pmid:22429572
Wiley JL et al. Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents. 2014 Eur. J. Pharmacol. pmid:24858366
Bermúdez-Siva FJ et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. 2006 Eur. J. Pharmacol. pmid:16423347
García Mdel C et al. Role of CGRP and GABA in the hypotensive effect of intrathecally administered anandamide to anesthetized rats. 2006 Eur. J. Pharmacol. pmid:16472800
Wiley J et al. Discriminative stimulus effects of anandamide in rats. 1995 Eur. J. Pharmacol. pmid:7781695
Pelorosso FG et al. The endocannabinoid anandamide inhibits kinin B1 receptor sensitization through cannabinoid CB1 receptor stimulation in human umbilical vein. 2009 Eur. J. Pharmacol. pmid:19022239
Walentiny DM et al. The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice. 2011 Eur. J. Pharmacol. pmid:21300050
Lau AH and Chow SS Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells. 2003 Eur. J. Pharmacol. pmid:12620517
García Mdel C et al. Impaired hypotensive responses induced by intrathecally injected drugs in fructose-fed rats. 2013 Eur. J. Pharmacol. pmid:23499700
Peroni RN et al. Participation of CGRP and prostanoids in the sex-linked differences of vascular anandamide effects in mesenteric beds of Sprague-Dawley rats. 2007 Eur. J. Pharmacol. pmid:17169358
Russo R et al. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. 2007 Eur. J. Pharmacol. pmid:17434479
Barg J et al. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. 1995 Eur. J. Pharmacol. pmid:8749028
Gifford AN et al. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). 1999 Eur. J. Pharmacol. pmid:10556675
Liu YC and Wu SN Block of erg current by linoleoylamide, a sleep-inducing agent, in pituitary GH3 cells. 2003 Eur. J. Pharmacol. pmid:12498905
Zygmunt PM et al. The anandamide transport inhibitor AM404 activates vanilloid receptors. 2000 Eur. J. Pharmacol. pmid:10822052
Wiley JL et al. Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice. 2005 Eur. J. Pharmacol. pmid:15740725
Zaniewska M et al. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. 2006 Eur. J. Pharmacol. pmid:16730696
Varga K et al. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. 1995 Eur. J. Pharmacol. pmid:7589169
Alptekin A et al. The effects of anandamide transport inhibitor AM404 on voltage-dependent calcium channels. 2010 Eur. J. Pharmacol. pmid:20171208
Randall MD et al. Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery. 1997 Eur. J. Pharmacol. pmid:9314035
Randall MD and Kendall DA Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. 1997 Eur. J. Pharmacol. pmid:9369375
Burkey TH et al. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. 1997 Eur. J. Pharmacol. pmid:9384246
Calignano A et al. Potentiation of anandamide hypotension by the transport inhibitor, AM404. 1997 Eur. J. Pharmacol. pmid:9389389
Begg M et al. Modulation of the release of endogenous gamma-aminobutyric acid by cannabinoids in the guinea pig ileum. 2002 Eur. J. Pharmacol. pmid:11755170
Giuffrida A et al. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. 2000 Eur. J. Pharmacol. pmid:11080522
Marichal-Cancino BA et al. Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats. 2013 Eur. J. Pharmacol. pmid:24076186
Wise LE et al. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. 2007 Eur. J. Pharmacol. pmid:17217945
Kagota S et al. 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor. 2001 Eur. J. Pharmacol. pmid:11275004
Calignano A et al. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. 2001 Eur. J. Pharmacol. pmid:11426841
Lisboa SF et al. Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. 2008 Eur. J. Pharmacol. pmid:18691568
Fride E et al. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. 2001 Eur. J. Pharmacol. pmid:11426843
Lay L et al. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse. 2000 Eur. J. Pharmacol. pmid:10720647
Sordelli MS et al. Cyclooxygenase-2 prostaglandins mediate anandamide-inhibitory action on nitric oxide synthase activity in the receptive rat uterus. 2012 Eur. J. Pharmacol. pmid:22554772
Someya A et al. Arachidonic acid release and prostaglandin F(2alpha) formation induced by anandamide and capsaicin in PC12 cells. 2002 Eur. J. Pharmacol. pmid:12206851
Ndong C et al. Cloning and pharmacological characterization of the dog cannabinoid CBâ‚‚receptor. 2011 Eur. J. Pharmacol. pmid:21871882
Rácz I et al. Anandamide effects on 5-HT(3) receptors in vivo. 2008 Eur. J. Pharmacol. pmid:18775693
Thors L and Fowler CJ Effect of nitric oxide donors on membrane tritium accumulation of endocannabinoids and related endogenous lipids. 2009 Eur. J. Pharmacol. pmid:19715690
Stanley CP et al. Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes. 2013 Eur. J. Pharmacol. pmid:24120371
Stengel PW et al. Inhaled anandamide reduces leukotriene D4-induced airway obstruction in guinea pigs. 2007 Eur. J. Pharmacol. pmid:17166495
Calignano A et al. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. 1997 Eur. J. Pharmacol. pmid:9537804
Berdyshev EV et al. Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. 1997 Eur. J. Pharmacol. pmid:9253958
Costa B et al. Chronic treatment with the endocannabinoid anandamide increases cytochrome P450 metabolizing system in the rat. 2002 Eur. J. Pharmacol. pmid:12163107
de Lago E et al. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. 2002 Eur. J. Pharmacol. pmid:12163112
Pertwee RG et al. Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. 1995 Eur. J. Pharmacol. pmid:7713152